Form 4: Ligand Pharmaceuticals CFO Acquires Shares Through Employee Stock Purchase Plan

Ligand Pharmaceuticals Inc.'s Chief Financial Officer, Octavio Espinoza, acquired 224 shares of common stock at $91.0775 per share through the company's Employee Stock Purchase Plan.

Summary

• Octavio Espinoza, Chief Financial Officer of Ligand Pharmaceuticals Inc. (LGND), acquired 224 shares of common stock.
• The acquisition occurred on June 30, 2025, at a price of $91.0775 per share.
• These shares were acquired under the Ligand Employee Stock Purchase Plan (ESPP).
• Following this transaction, Octavio Espinoza beneficially owns a total of 29,852 shares of common stock.
• The transaction is exempt under SEC Rules 16b-3(d) and 16b-3(c).

Sentiment

Score: 7

Explanation: The acquisition of shares by a Chief Financial Officer through an employee stock purchase plan is generally a positive signal, indicating management's confidence in the company's future, though the amount is relatively small compared to total holdings.

Positives

• Chief Financial Officer Octavio Espinoza increased his direct ownership in the company by acquiring 224 shares.
• The acquisition was made through the Ligand Employee Stock Purchase Plan, indicating participation in employee benefit programs and potential confidence in the company's future.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May view the CFO's purchase as a positive signal of confidence in the company's prospects.
• Employees: The transaction highlights the existence and utilization of an Employee Stock Purchase Plan, which can be a valuable benefit for employees.

Key Dates

Keywords

Ligand Pharmaceuticals, LGND, Octavio Espinoza, Chief Financial Officer, CFO, SEC Form 4, Insider Transaction, Stock Acquisition, Employee Stock Purchase Plan, ESPP, Common Stock